NCT06016179View on ClinicalTrials.gov

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions
Malignant Pleural EffusionMalignant Ascites
Interventions
DRUG

Tocilizumab

Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.

Trial Locations (1)

15213

RECRUITING

Allegheny Health Network Cancer Institute, Pittsburgh

All Listed Sponsors
lead

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

OTHER